PMID- 28512771
OWN - NLM
STAT- MEDLINE
DCOM- 20170726
LR  - 20170726
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 102
IP  - 2
DP  - 2017 Aug
TI  - Negative Cardiovascular Consequences of Small Molecule Immunosuppressants.
PG  - 269-276
LID - 10.1002/cpt.738 [doi]
AB  - Immunosuppressants are critical after transplantation and prescribed as 
      immune-modulators for autoimmune disorders and glomerulonephritides. 
      Immunosuppressants include large (e.g., thymoglobulin, alemtuzumab, and 
      rituximab) and small molecules (e.g., corticosteroids, calcineurin inhibitors, 
      antimetabolites, and mammalian target of rapamycin (mTOR) inhibitors). The 
      majority of the small molecules worsen traditional cardiovascular risks. This 
      review describes cardiovascular risks of small molecule immunosuppressants: 
      corticosteroids, calcineurin inhibitors (tacrolimus and cyclosporine), and mTOR 
      inhibitors (rapamycin), by categorizing these risks into two categories: ischemic 
      heart disease and nonischemic cardiac effects.
CI  - (c) 2017 American Society for Clinical Pharmacology and Therapeutics.
FAU - Chakkera, H A
AU  - Chakkera HA
AD  - Division of Transplantation, Mayo Clinic, Phoenix, Arizona, USA.
FAU - Sharif, A
AU  - Sharif A
AD  - Division of Nephrology and Transplantation, Queen Elizabeth Hospital, Birmingham, 
      United Kingdom.
FAU - Kaplan, B
AU  - Kaplan B
AD  - Division of Transplantation, Mayo Clinic, Phoenix, Arizona, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Animals
MH  - Autoimmune Diseases/drug therapy/immunology/physiopathology
MH  - Cardiovascular Diseases/*chemically induced/immunology/physiopathology
MH  - Cardiovascular Physiological Phenomena/*drug effects/immunology
MH  - Clinical Trials as Topic/methods
MH  - Diabetes Mellitus/chemically induced/immunology/physiopathology
MH  - Humans
MH  - Hyperlipidemias/chemically induced/immunology/physiopathology
MH  - Immunosuppressive Agents/*adverse effects/therapeutic use
EDAT- 2017/05/18 06:00
MHDA- 2017/07/27 06:00
CRDT- 2017/05/18 06:00
PHST- 2017/03/15 00:00 [received]
PHST- 2017/05/05 00:00 [revised]
PHST- 2017/05/10 00:00 [accepted]
PHST- 2017/05/18 06:00 [pubmed]
PHST- 2017/07/27 06:00 [medline]
PHST- 2017/05/18 06:00 [entrez]
AID - 10.1002/cpt.738 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2017 Aug;102(2):269-276. doi: 10.1002/cpt.738.